Further studies suggested that shRNA or small-molecule inhibitor mediated suppression of BRD4 resulted in robust antileukemic effects in vitro and in vivo, with a terminal myeloid differentiation and an elimination of leukemia stem cells (Zuber et al. 2011), demonstrating that BRD4 is a therapeutic target for acute myeloid leukemia (AML). Here, BRD4 is linked to acute myeloid leukemia.